Global Asthma and COPD Drug Market: Market Research, Size, Growth, Trend, Analysis

According to a recent market study published by Transparency Market Research (TMR), the global asthma and COPD market was worth USD 25,102.3 million in 2010, which is expected to reach USD 26,965.5 million in 2017 along with a CAGR figure of 1.03% over the forecasted by 2017.

The current asthma and COPD market is primarily driven by increasing patient population. It is also growing due to factors such as price erosion and expiry of patents of leading drug brands in the market. However, it is estimated that in the next five years, the global asthma and COPD drug market is expected to grow slowly and steadfast. In 2010, the asthma drug segment dominated the overall asthma and COPD market at USD 14,509.1 million. In the same year, the COPD segment was projected to be worth USD 10,593.2 million and is expected to reach USD 12,619.8 million in 2017.

In medical parlance, asthma is defined as a respiratory condition wherein, the airways through which a body breathes becomes inflamed and constricted due to one or more environmental triggers. This condition is considered to be a serious disorder in a human body and over 300 million people suffer from asthma in the world. Asthma is often treated with drug therapy and by avoiding any type of triggers. The total drug market for asthma is worth over $15 billion.

Get Sample Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=145

Asthma being one of the most common disorders is defined as a respiratory condition that affects the airway system of our body wherein, the tubes that carry the air in and out of the body is inflamed and constricted due to one or more environmental triggers. Asthma is a type of a chronic disease, and if this potentially fatal condition is left untreated, there are chances for the condition to worsen making a person suffer from extreme respiratory problems to breathe the environmental air in any form.

People who suffer from the asthma attacks have swollen airways’ walls that get narrower when irritated causing sensations within their ENT area. This makes it difficult for the person to take in subsequent amount of air for a hassle-free inhale. Likewise, the airways' walls of the patients suffering from COPD are almost similar. Patients suffering from asthma and COPD conditions have airways’ walls inflamed with mucus.

Worldwide, over 300 million people suffer from asthma which has subsequently aggravated the drug market to reach a figure worth over $15 billion. Asthma can be treated by drug therapy or by avoiding environmental triggers.

In Europe, LABA / ICS combinations and LTA (Montelukast) drugs are more popular for asthma and COPD treatment. Merck's branded product Singulair contains Montelukast sodium, which is a leading oral anti-asthma and anti-allergy drug. Singulair is one of the trusted drugs for the treatment of chronic asthma, and for the relief of symptoms of seasonal allergic rhinitis. Currently, Montelukast is the largest selling anti-asthmatic drug worldwide.

Report tailored as you need for Customize: http://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=145

For COPD patients, physicians also prescribe use of the long-acting muscarinic antagonist (LAMA) Spiriva (Boehringer Ingelheim/Pfizer).  Spiriva is expected to constitute about xxx% of the U.S. COPD drug sales in 2012. The LABA/LAMA combination is preferred for the treatment of COPD. Several combinations are in late-stage development, including vilanterol / GSK-573719 (GlaxoSmithKline/Theravance), indacaterol / glycopyrronium (Novartis), and olodaterol / tiotropium (Boehringer Ingelheim).
 
Key products exposed to generic competition include GlaxoSmithKline’s Advair Boehringer Ingelheim/Pfizer’s Spiriva and Merck’s Singulair, which will lose active ingredient patent protection in the U.S. in 2011 and 2012 respectively. Patent expiration of Merck’s Singulair, which generated sales of around USD 3.3 billion in 2010, will be a key restraint for the overall Asthma market as generic entry in the United States, Europe and Japan will reduce sales of branded Singulair.
 
Asthma is characterized by recurrent attacks of coughing, chest-tightening, breathlessness and wheezing as the airways narrow and swell that vary in severity and frequency. This chronic disease is most common among children.

Browse the Recent Press Release : http://www.transparencymarketresearch.com/pressrelease/asthma-and-copd-market.htm

About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.
 
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
 
Contact
Mr. Sudip Saha
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/